KemPharm is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system (CNS) and rare disease indications that allow it to target areas with unmet needs. Co.'s prodrug product candidate pipeline is focused on the idiopathic hypersomnia (IH) and other CNS/rare diseases. Co.'s approved product, AZSTARYS®, a once-daily treatment for attention deficit hyperactivity disorder in patients, age six years and older, contains its prodrug, serdexmethylphenidate (SDX). Co.'s primary clinical development product candidate, KP1077, is based on SDX, its prodrug of d-methlyphenidate and is in development for the treatment of IH and narcolepsy. We show 34 historical shares outstanding datapoints in our KMPH shares outstanding history coverage, used to compute KMPH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KMPH market cap history over the course of time is important for investors
interested in comparing KMPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KMPH versus a peer is one thing; comparing
KMPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KMPH can fluctuate over the course of history.
With this page we aim to empower investors researching KMPH by allowing them to research the KMPH market cap history. |
Free KMPH Email Alerts:
Video: The Importance of Market Cap
